One of the world’s largest pharmaceutical companies, Allergan, has settled a lawsuit filed by patients who took its Alzheimer’s drug Namenda. The suit alleged that Allergan conspired with its competitor Mylan NV to delay alternative drugs and that it worked to push back the release of generic options.
While paying $750 million to class action plaintiffs, Allergan did not admit wrongdoing. It will count the payment against its earnings in Q3 of 2019. Read the full report in the article at Business Insurance.